iiinova — where your digital self keeps evolving

pharmaphorum @pharmaphorum.bsky.social · 09/10/2026

#AI-powered #drugdiscovery company #IambicTherapeutics has announced the terms of its #Nasdaq #IPO, pitching at a valuation of more than $800 million if all goes through as planned. buff.ly/hkm8d8S

000

pharmaphorum @pharmaphorum.bsky.social · 09/10/2026

#Pfizer has claimed #FDA approval for front-line maintenance use of its oral #HER2inhibitor #Tukysa in #breastcancer, an indication it hopes will unlock the product's growth potential. pharmaphorum.com/news/pfizers...

000

pharmaphorum @pharmaphorum.bsky.social · 08/10/2026

#US pharma trade organisation #PhRMA is challenging the #Trump administration's #GLOBE model for Most-Favoured Nation (#MFN) #pricing in #Medicare Part B in court, accusing it of government overreach. pharmaphorum.com/news/phrma-s...

000

pharmaphorum @pharmaphorum.bsky.social · 07/10/2026

#MSD has been rocked by a #courtjudgment ordering it to stop manufacturing and selling its #subcutaneous formulation of cancer immunotherapy #Keytruda in eight #Europeanmarkets. pharmaphorum.com/news/msd-ord...

000

pharmaphorum @pharmaphorum.bsky.social · 07/10/2026

#ViiVHealthcare's long-acting injectable #HIV treatment, #Cabenuva, has proved to be more effective than daily oral therapy for people in whom the virus is unsuppressed despite antiretroviral therapy (ART). pharmaphorum.com/news/viivs-c...

000

pharmaphorum @pharmaphorum.bsky.social · 06/10/2026

The governor of #NewYork has said that rising cases of #measles constitute a "statewide #disaster #emergency," the first such announcement since cases of the #infection started to surge around the start of 2025 pharmaphorum.com/news/new-yor...

000

pharmaphorum @pharmaphorum.bsky.social · 06/10/2026

Shares in #Vaxcyte have rocketed on the revelation of phase 3 trial data for its #pneumococcalvaccine (PCV) candidate VAX-31, which suggests it could be a threat to already-marketed shots from Pfizer and MSD. pharmaphorum.com/news/vaxcyte...

000

pharmaphorum @pharmaphorum.bsky.social · 06/10/2026

#EliLilly's noncovalent BTK inhibitor #Jaypirca has been cleared by the #FDA in its first frontline indication for chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL). pharmaphorum.com/news/lillys-...

000

pharmaphorum @pharmaphorum.bsky.social · 05/10/2026

The 2026 #NobelPrize in Physiology or #Medicine has been awarded jointly to three scientists – Karl Deisseroth, Peter Hegemann, and Georg Nagel – for their work on light-gated ion channels and #optogenetics. pharmaphorum.com/news/nobel-p...

000

pharmaphorum @pharmaphorum.bsky.social · 05/10/2026

The #FDA has extended its review of #Novo's experimental #haemophiliaA drug #denecimig because of ongoing remediation work at a facility that will be used to manufacture the #FactorVIIIamimetic. pharmaphorum.com/news/novo-fa...

000

pharmaphorum @pharmaphorum.bsky.social · 02/10/2026

The #UK is putting £80 million ($105 million) in #funding behind nine #technologies that it hopes will be able to diagnose #dementia more quickly. pharmaphorum.com/news/uk-puts...

010

pharmaphorum @pharmaphorum.bsky.social · 30/09/2026

#AbbVie's long-acting anti-IL-13 antibody #zumilokibart – the main asset in its $10.9 billion takeover of Apogee Therapeutics – has hit the mark in a phase 2b trial in #atopicdermatitis, its lead indication. pharmaphorum.com/news/apogee-...

000

pharmaphorum @pharmaphorum.bsky.social · 30/09/2026

#EliLilly's triple G agonist #retatrutide has achieved impressive #weightloss in patients with #type2diabetes and #obesity, boosting its credentials as the next big thing in #cardiometabolicdiseases. pharmaphorum.com/news/lilly-f...

000

pharmaphorum @pharmaphorum.bsky.social · 28/09/2026

The first product from #AbbVie's $8.7 billion takeover of #Cerevel two years ago – #Parkinsonsdisease therapy #tavapadon – has been approved by the #FDA. pharmaphorum.com/news/abbvies...

000

pharmaphorum @pharmaphorum.bsky.social · 28/09/2026

Patients with #fibrodysplasiaossificansprogressiva (FOP) in the #US will soon have the option of treatment with another #dailypill after the #FDA approved #MirumPharma's ALK2 inhibitor, Atebrioz, for the #rarebonedisease. pharmaphorum.com/news/fda-app...

000

pharmaphorum @pharmaphorum.bsky.social · 28/09/2026

#MSD and #DaiichiSankyo's regulatory efforts for their antibody-drug conjugates (#ADCs) for cancer have stuttered again, with a withdrawn filing for #lungcancer candidate ifinatamab deruxtecan (I-DXd) in the US. pharmaphorum.com/news/msd-dai...

000

pharmaphorum @pharmaphorum.bsky.social · 25/09/2026

#AstraZeneca could be just months away from #FDA approval of a new #bladdercancer indication for its #PDL1inhibitor #Imfinzi, which is viewed as key to meeting its sales ambitions for the drug. pharmaphorum.com/news/fda-sta...

000

pharmaphorum @pharmaphorum.bsky.social · 24/09/2026

The #FDA has approved #EliLilly's once-weekly #basalinsulin product #Onswik for adults with #type2diabetes, setting up a market tussle with Novo over its recently launched Awiqli. pharmaphorum.com/news/lillys-...

010

pharmaphorum @pharmaphorum.bsky.social · 23/09/2026

There has been a flurry of #clinicalreadouts for new #weightlosstherapies in the last few days, with #Roche, #VikingTherapeutics, and #Syntis all showing off new drug candidates. buff.ly/IIdTSVq

000

pharmaphorum @pharmaphorum.bsky.social · 23/09/2026

#Roche has staked a claim to the increasingly crowded #IgAnephropathy (IgAN) category, which has seen half a dozen new therapies approved by the FDA in the last decade, with plenty more in late-stage development. buff.ly/gqyXUsE

000

pharmaphorum @pharmaphorum.bsky.social · 23/09/2026

#Europe's top #pharma groups have called for #governments in the region to stop viewing #newmedicines as a #cost to suppress, rather than "one of the best #investments [they] can make." pharmaphorum.com/news/pharma-...

010

pharmaphorum @pharmaphorum.bsky.social · 22/09/2026

A #consumeradvocacygroup has scrutinised some of the #MostFavouredNation (MFN) #pricing deals the #Trump administration has announced with 27 #pharma companies and concludes that claims about the savings they deliver are smoke and mirrors. pharmaphorum.com/news/advocac...

000

pharmaphorum @pharmaphorum.bsky.social · 22/09/2026

The appetite among #USbiotechs for #IPOs shows no signs of being satisfied, with three more companies – #ADARxPharma, #TRexBio, and #RetensionPharma – joining the lunch queue. pharmaphorum.com/news/adarx-t...

000

pharmaphorum @pharmaphorum.bsky.social · 21/09/2026

Facing considerable pressure in its diabetes and obesity franchises, #Novo has revealed a plan to #launch five or more blockbusters between now and 2030 that it estimates will swell its annual #revenues by around $23 billion. pharmaphorum.com/news/under-p...

010

pharmaphorum @pharmaphorum.bsky.social · 21/09/2026

#AstraZeneca's rare disease unit #Alexion has claimed a positive opinion from the #EMA's human medicines committee for #generalisedmyastheniagravis (gMG) therapy #Klygefa. pharmaphorum.com/news/azs-gmg...

000

pharmaphorum @pharmaphorum.bsky.social · 18/09/2026

The chairs of six #UK #parliamentarycommittees have asked the #NationalAuditOffice (NAO) to investigate the #UKUSpharmaagreement and gauge its impact on #publicexpenditure. pharmaphorum.com/news/mps-see...

000

pharmaphorum @pharmaphorum.bsky.social · 18/09/2026

This week's biggest #biotech #venturefinancings include sizeable rounds for #SlingTherapeutics, #CirclePharma, and #RegCell. pharmaphorum.com/news/which-b...

000

pharmaphorum @pharmaphorum.bsky.social · 17/09/2026

Generating good-quality #patientexperiencedata (PED) is becoming increasingly important for #medicinedevelopment, and #BoehringerIngelheim has launched a hub to help #patientorganisations gather it effectively. buff.ly/s8J8T5C

000

pharmaphorum @pharmaphorum.bsky.social · 15/09/2026

As the #WorldConferenceonLungCancer (WCLC) draws to a close, here is some of the late-breaking #clinicaltrialdata that made waves at the congress. pharmaphorum.com/news/wclc-lu...

000

pharmaphorum @pharmaphorum.bsky.social · 14/09/2026

Just a week after getting FDA approval as a frontline treatment for HR-positive, HER2-negative #breastcancer, #AstraZeneca's #Etcamah has missed the mark in a trial designed to expand its label. pharmaphorum.com/news/azs-etc...

000